PMID- 37909957
OWN - NLM
STAT- MEDLINE
DCOM- 20231102
LR  - 20231102
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 43
IP  - 11
DP  - 2023 Nov
TI  - Efficacy and Safety of Oxaliplatin-based Regimens as First-line Chemotherapy in 
      Elderly Patients With Metastatic Colorectal Cancer.
PG  - 5099-5105
LID - 10.21873/anticanres.16710 [doi]
AB  - BACKGROUND/AIM: Metastatic colorectal cancer (mCRC) is mainly a disease of the 
      elderly. The aim of this retrospective study was to investigate the efficacy and 
      safety of oxaliplatin-based regimens as first-line chemotherapy in elderly 
      patients with mCRC. PATIENTS AND METHODS: We recruited mCRC patients aged >/=75 
      years who were treated with oxaliplatin-based chemotherapy as first-line therapy 
      from October 2011 to November 2020. Primary outcome was median progression-free 
      survival (PFS) and incidence of adverse events, while secondary outcomes included 
      overall survival (OS), relative dose intensity (RDI) and tumor response rate. 
      RESULTS: The study enrolled 41 patients with mCRC aged >/=75 years. Median PFS and 
      OS were 9.3 months and 38.9 months, respectively. Median rate of starting dose 
      per standard dose and median RDI of L-OHP were 94.6% [interquartile range 
      (IQR)=80.0-100] and 52.4% (IQR=30.2-71.1), respectively. The most common adverse 
      events of grade >/=3 were neutropenia (21.4%), high blood pressure (16.7%), and 
      anorexia (14.3%). CONCLUSION: Although the RDI of L-OHP drug was low, the PFS, 
      OS, and incidence of adverse events were similar to previous reports of 
      oxaliplatin-based regimens not limited to the elderly. Oxaliplatin-based regimens 
      as first-line chemotherapy may be safely and effectively adapted to patients aged 
      >/=75 years with mCRC by continuing chemotherapy with implementation of a reduction 
      and discontinuation of anticancer drugs depending on adverse events.
CI  - Copyright (c) 2023 International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Yamamoto, Seiji
AU  - Yamamoto S
AD  - Department of Pharmaceutical Health Care and Science, School of Pharmacy, Aichi 
      Gakuin University, Aichi, Japan.
FAU - Fujii, Hironori
AU  - Fujii H
AD  - Department of Pharmacy, Gifu University Hospital, Gifu, Japan.
FAU - Murayama, Kotaro
AU  - Murayama K
AD  - Department of Pharmaceutical Health Care and Science, School of Pharmacy, Aichi 
      Gakuin University, Aichi, Japan.
FAU - Iihara, Hirotoshi
AU  - Iihara H
AD  - Department of Pharmacy, Gifu University Hospital, Gifu, Japan.
FAU - Watanabe, Daichi
AU  - Watanabe D
AD  - Department of Pharmacy, Gifu University Hospital, Gifu, Japan.
FAU - Yamada, Yunami
AU  - Yamada Y
AD  - Department of Pharmacy, Gifu University Hospital, Gifu, Japan.
FAU - Kobayashi, Ryo
AU  - Kobayashi R
AD  - Department of Pharmacy, Gifu University Hospital, Gifu, Japan.
AD  - Laboratory of Advanced Medical Pharmacy, Gifu Pharmaceutical University, Gifu, 
      Japan.
FAU - Kiyama, Shigeru
AU  - Kiyama S
AD  - Department of Gastroenterological Surgery, Pediatric Surgery, Gifu University 
      Graduate School of Medicine, Gifu, Japan.
FAU - Makiyama, Akitaka
AU  - Makiyama A
AD  - Cancer Center, Gifu University Hospital, Gifu, Japan.
AD  - Center for One Medicine Innovative Translational Research, Gifu University 
      Institute for Advanced Study, Gifu, Japan.
FAU - Urano, Kimihiko
AU  - Urano K
AD  - Department of Pharmaceutical Health Care and Science, School of Pharmacy, Aichi 
      Gakuin University, Aichi, Japan.
FAU - Matsuhashi, Nobuhisa
AU  - Matsuhashi N
AD  - Department of Gastroenterological Surgery, Pediatric Surgery, Gifu University 
      Graduate School of Medicine, Gifu, Japan.
FAU - Suzuki, Akio
AU  - Suzuki A
AD  - Department of Pharmacy, Gifu University Hospital, Gifu, Japan; 
      suzuki.akio.k5@f.gifu-u.ac.jp.
AD  - Laboratory of Advanced Medical Pharmacy, Gifu Pharmaceutical University, Gifu, 
      Japan.
FAU - Matsuura, Katsuhiko
AU  - Matsuura K
AD  - Department of Pharmaceutical Health Care and Science, School of Pharmacy, Aichi 
      Gakuin University, Aichi, Japan.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 04ZR38536J (Oxaliplatin)
SB  - IM
MH  - Aged
MH  - Humans
MH  - Oxaliplatin/adverse effects
MH  - Retrospective Studies
MH  - *Colonic Neoplasms
MH  - *Rectal Neoplasms
MH  - *Neutropenia
OTO - NOTNLM
OT  - Colorectal cancer
OT  - elderly patients
OT  - oxaliplatin
EDAT- 2023/11/01 12:42
MHDA- 2023/11/02 12:44
CRDT- 2023/11/01 10:43
PHST- 2023/08/08 00:00 [received]
PHST- 2023/09/04 00:00 [revised]
PHST- 2023/09/06 00:00 [accepted]
PHST- 2023/11/02 12:44 [medline]
PHST- 2023/11/01 12:42 [pubmed]
PHST- 2023/11/01 10:43 [entrez]
AID - 43/11/5099 [pii]
AID - 10.21873/anticanres.16710 [doi]
PST - ppublish
SO  - Anticancer Res. 2023 Nov;43(11):5099-5105. doi: 10.21873/anticanres.16710.